Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · IEX Real-Time Price · USD
41.39
-0.55 (-1.31%)
At close: May 17, 2024, 4:00 PM
41.25
-0.14 (-0.34%)
After-hours: May 17, 2024, 4:33 PM EDT
Vera Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Vera Therapeutics stock have an average target of 36.71, with a low estimate of 22 and a high estimate of 68. The average target predicts a decrease of -11.31% from the current stock price of 41.39.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for VERA stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $57 → $68 | Strong Buy | Maintains | $57 → $68 | +64.29% | May 10, 2024 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +35.30% | Apr 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $27 → $56 | Strong Buy | Maintains | $27 → $56 | +35.30% | Mar 27, 2024 |
| Wedbush | Wedbush | Hold Maintains $21 → $34 | Hold | Maintains | $21 → $34 | -17.85% | Mar 21, 2024 |
| Wedbush | Wedbush | Hold Maintains $16 → $21 | Hold | Maintains | $16 → $21 | -49.26% | Jan 26, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.20
from -2.25
EPS Next Year
-2.37
from -2.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 85.8M | 323.0M | 653.0M |
| Avg | n/a | n/a | 41.6M | 174.6M | 416.9M |
| Low | n/a | n/a | 7.7M | 79.7M | 210.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 676.7% | 274.1% |
| Avg | - | - | - | 319.8% | 138.8% |
| Low | - | - | - | 91.6% | 20.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.08 | -1.94 | -2.25 | 0.15 | 2.73 |
| Avg | -2.20 | -2.37 | -2.71 | -0.21 | 2.18 |
| Low | -2.57 | -3.11 | -3.33 | -0.40 | 1.53 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.